AMEX : KAL
Randall D. Lewis, CFA - Analyst
November 30, 2005
Stock Price $1.19
We are initiating a Buy rating for Callisto Pharmaceuticals, Inc. (AMEX: KAL). Callisto is an emerging biopharmaceutical company whose primary focus is the clinical development of drugs to treat cancer and gastrointestinal inflammation.
View This Report in Acrobat Format
|
 |
|
